Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles

Abstract: Convection-enhanced delivery (CED) is a novel approach for delivering drugs directly into brain tumors by intracranial infusion, enabling the distribution of high drug concentrations over large tissue volumes. This study was designed to present a method for binding methotrexate (MTX) to unique crystalline, highly ordered and superparamagnetic maghemite nanoparticles via human serum albumin (HSA) coating, optimized for CED treatments of gliomas. Naked nanoparticles and HSA- or polyethylene glycol (PEG)-coated nanoparticles with/without MTX were studied. In vitro results showed no toxicity and a similar cell-kill efficacy of the MTX-loaded particles via HSA coating to that of free MTX, while MTX-loaded particles via PEG coating showed low efficacy. In vivo, the PEG-coated nanoparticles provided the largest distributions in normal rat brain and long clearance times, but due to their low efficacy in vitro, were not considered optimal. The naked nanoparticles provided the smallest distributions and shortest clearance times. The HSA-coated nanoparticles (with/without MTX) provided good distributions and long clearance times (nearly 50% of the distribution volume remained in the brain 3 weeks post treatment). No MTX-related toxicity was noted. These results suggest that the formulation in which HSA was bound to our nanoparticles via a unique precipitation method, and MTX was bound covalently to the HSA, could enable efficient and stable drug loading with no apparent toxicity. The cell-kill efficacy of the bound MTX remained similar to that of free MTX, and the nanoparticles presented efficient distribution volumes and slow clearance times in vivo, suggesting that these particles are optimal for CED.

Keywords: convection-enhanced delivery, nanoparticles, methotrexate, magnetic resonance imaging, rat brain

Introduction

Malignant primary brain tumors, especially the highly malignant recurrent glioblastoma multiforme (GBM), are fatal within months of diagnosis. Chemotherapy confers no significant survival advantage, in part due to the poor penetration of most chemotherapeutic drugs across the blood–brain barrier (BBB). Convection-enhanced delivery (CED) is a novel approach to deliver drugs directly into brain tumors. It is based on delivering a continuous infusion of drugs via intracranial catheters, enabling the convective distribution of high drug concentrations over large volumes of tissue while avoiding systemic toxicity.1-4

Efficient CED formation depends on various physical/physiological parameters.5,6 Previous CED-based clinical trials showed a significant diversity in the extent of convection among patients and drugs. We have previously shown that CED formation/extent may be significantly improved by increasing infusate viscosities.7 Efficient CED
is currently limited to small molecules (<200 kDa). We have recently demonstrated the application of our increased efficacy methodologies to enable efficient CED of maghemite nanoparticles in a normal rat brain model. The authors have also established the validity of using magnetic resonance imaging (MRI) for depicting the distribution of the convected maghemite nanoparticles in the brain. This study also demonstrated the long clearance time of the maghemite nanoparticles from the brain (weeks to months) with no evidence of toxicity.

Methotrexate (MTX) is a folic acid analog used as a chemotherapeutic agent. As folate receptors are over expressed on the cell membranes of many types of cancer cells, MTX is one of the most widely used drugs for the treatment of many forms of cancer, including tumors of the brain, breast, ovaries, and several leukemias. However, MTX is limited by its low solubility, dose-related toxicity, lack of selectivity, rapid diffusion throughout the body, short half-life in the bloodstream, and drug resistance by target cells. Recent literature indicates increasing interest in binding MTX to nanoparticles to alter its pharmacokinetic behavior, enhance tumor targeting, reduce toxicity, and overcome drug-resistance mechanisms. In this study we used the combination of nanoparticles with CED, thus avoiding the main limitation introduced by systemic administration.

Magnetic nanoparticles are considered to be spherical particles with magnetic properties in sizes ranging from a few nm to approximately 100 nm. These particles, because of their spherical shape, large surface area and magnetic properties, may have a wide range of potential applications. Magnetic nanoparticles that have been approved by the FDA are Feridex and Combidex, used as MRI contrast agents. These are prepared by reacting ferrous and ferric salts in an aqueous phase under severe basic conditions, producing a broad size distribution (considered a potential source of toxicity). Particles prepared this way often suffer from lack of stability due to agglomeration, and the technology to covalently bind bioactive reagents (ie, proteins) to their surface, particularly to the smallest available particles, is still obscure. Furthermore, since these nanoparticles are prepared under basic conditions, the encapsulation of sensitive bioactive reagents, eg, proteins, within the nanoparticles for drug delivery and controlled-release applications is not efficient due to denaturation of the proteins. Other highly investigated superparamagnetic nanoparticles, MION (monocrystalline iron oxide nanocompounds and AMI-25 (Advanced Magnetics, Inc, Cambridge, MA), also prepared similarly by the interaction of ferrous and ferric salts in an aqueous phase under basic conditions, possess similar limitations and are not yet suitable for clinical use.

The authors have recently prepared and characterized a new uniform magnetic maghemite (γ-Fe₂O₃) nanoparticles, formed via controlled nucleation and then the growth of thin films of maghemite onto gelatin/iron oxide nuclei. These particles can be prepared in sizes of 15–80 nm. They are biodegradable, nontoxic and have a narrow size distribution. Their preparation is simple and can be performed close to physiological pH, with a yield of almost 100%. These nanoparticles are also superparamagnetic, enabling real-time imaging with MRI. Using these nanoparticles, biocompatible stabilized particles containing various functional groups are prepared by coating with a variety of polymers including proteins, polysaccharides such as dextran, and polyethylene glycols. The functional groups of these coatings can then be used for the covalent binding of bioactive reagents such as drugs, proteins, antibodies and enzymes, to the surface of these maghemite nanoparticles.

Since maghemite nanoparticles have been shown to provide increased uptake in cancer cells versus normal cells, and since human serum albumin (HSA) and polyethylene glycol (PEG) have been shown to increase the intake of MTX into cancer cells, this study focuses on developing a methodology to bind MTX, a well-proven anti-tumor agent active in GBM, via HSA to the magnetic nanoparticles. The uptake of the drug-loaded particles and the efficacy of the drug-loaded particles versus the efficacy of the free drug were studied in vitro, followed by in vivo CED experiments to study the efficacy of distribution and clearance patterns of the nanoparticles in the brain.

The efficient CED of nanoparticles may enable the use of drugs and/or drug carriers that until now were considered inappropriate for convection treatment. Nanoparticles as drug carriers may enable the real-time depiction of particle distribution in the tissue, provide slow drug release, enable the delivery of larger therapeutic agents, and allow targeted drug delivery.

Materials and methods

In vitro and in vivo experimental outline

To obtain methotrexate-loaded maghemite nanoparticles, which are both effective in treating cancer cells, yet nontoxic to a normal brain, and taking into account the fact that animal brain tumor models do not simulate human tumors as regards consistency (and therefore are suboptimal for convection-based studies), the experiments were performed separately.
in vitro and in vivo. The in vitro experiments were designed to establish the anti-tumor efficacy of the drug-loaded particles and confirm that the vehicles (the nonloaded particles) were nontoxic. In these experiments, 9L gliosarcoma cells were incubated with the drug-loaded particles and controls for 48 hours. Following the incubation period, the cells were counted and the cell kill of each treatment was calculated. Once the drug-loaded particles were shown to be effective and the nonloaded particles were shown to be nontoxic, they were subjected to further studies in vivo.

An additional in vitro experiment was designed to determine the efficacy of the penetration of the nanoparticles into the cells, using MRI. In this experiment the cells were incubated for 24 hours with the nanoparticles. The cells were then rinsed and a pellet was prepared. Pellet vials were placed in the MRI together with calibration vials containing free nanoparticles at different concentrations. The γ-Fe₂O₃ concentration of the pellets was determined by comparing the contrast of the pellet vials and the calibration vials, as depicted in the magnetic resonance (MR) images.

The in vivo experiments were designed to study the distribution efficacy of the different particles in normal rat brains, to assess the clearance time from the brain, and to assess the toxicity to a normal brain. The tested solutions were infused into the rats’ brains through an intracranial catheter. The rats were scanned by MRI immediately after the infusion and then once a week, and thereafter for a period of 3 weeks. In addition, the rats were weighed once a week. The distribution efficacy was determined from the volumes of distribution, calculated from the MR images acquired immediately post treatment. The clearance time from the brain was determined by following the changes in the volume of distribution as a function of time, throughout the 3-week follow-up. Toxicity was determined by survival and weight gain throughout the 3-week follow-up.

### Materials

Methotrexate (MTX), glycine, divinyl sulfone (DVS), triethylamine (TEA), dimethyl sulfoxide (DMSO), FeCl₂, NaNO₃, potassium persulfate, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-hydroxysulfo succinimide (sulfo NHS), NaOH, gelatin (from porcine skin), human serum albumin (HSA), polyethylene glycol (PEG, MW 400), PEG (MW 400) methacrylate (PEGMA), PEG dimethacrylate (PEGDMA) and amino terminated PEGMA (NH₂PEGMA) were all purchased from Sigma (Rehovot, Israel). Salts for buffers were purchased from Bio-Lab Ltd (Jerusalem, Israel). Formaldehyde was purchased from Gadot Biochemical Industries, Ltd (Haifa Bay, Israel). Water was purified by passing deionized water through an Elgastat Spectrum reverse osmosis system (Elga Ltd, High Wycombe, UK).

### Synthesis of the maghemite nanoparticles (γ-Fe₂O₃)

Maghemite nanoparticles (γ-Fe₂O₃) of narrow size distribution were prepared by nucleation followed by the controlled growth of iron oxide thin films onto the gelatin/iron oxide nuclei, as previously described. Briefly, γ-Fe₂O₃ of 19.8 ± 4.7 nm dry diameter were prepared by adding a FeCl₂ aqueous solution (10 mmol/5 mL in 0.1 N HCl) to 80 mL of an aqueous solution containing 240 mg of porcine gelatin, followed by the addition of a NaNO₃ solution (7 mmol/5 mL in H₂O). After a reaction time of 10 minutes, a NaOH aqueous solution (1 N) was added until a pH of 9.5 was obtained. This procedure was repeated four more times. During the entire procedure, the aqueous suspension was agitated at 60°C and kept in an inert environment. The formed γ-Fe₂O₃ nanoparticles were then washed from excess reagents with H₂O using magnetic columns.

### Physical adsorption of HSA onto the maghemite nanoparticles (γ-Fe₂O₃–HSA) by precipitation

Ten milligrams of HSA was added to 50 mL of the γ-Fe₂O₃ nanoparticles dispersed in water (2 mg/mL). The reaction mixture was then shaken at pH 9.5 and 60°C for 24 hours, and then cooled gradually to room temperature. The obtained γ-Fe₂O₃–HSA nanoparticles (— is a symbol for the HSA physical coating obtained by precipitation) were then washed from excess HSA with phosphate-buffered saline by magnetic columns.

### Polymerization of polyethylene glycol acrylate derivatives on the surface of the maghemite nanoparticles (γ-Fe₂O₃–PEG)

Polymerization of PEGMA monomers on the surface of the maghemite nanoparticles was accomplished by mixing 25 mL of the maghemite nanoparticles dispersed in a bicarbonate buffer (0.1 M, pH 8.3, 4 mg/mL) with 0.35 mL of PEGMA, 0.05 mL of PEG dimethacrylate (PEGDMA), 0.1 mL of NH₂PEGMA, and 24 mg of potassium persulfate dissolved in 25 mL of a bicarbonate buffer (0.1 M, pH 8.3). For the polymerization process, the above mixture was shaken at 73°C for 4 hours. The formed γ-Fe₂O₃–PEG-NH₂ particles were then washed from excess monomers by magnetic columns.
Physical conjugation of methotrexate to the HSA-coated nanoparticles (γ-Fe₂O₃−HSA−MTX)

MTX was physically conjugated to the HSA coated nanoparticles, γ-Fe₂O₃−HSA, by adding 1 mg of MTX dissolved in 1 mL of DMSO to 20 mL of the nanoparticle dispersion in PBS (1 mg/mL). The reaction mixture was then shaken at room temperature for 18 hours. The obtained dispersion in PBS (1 mg/mL). The reaction mixture was dissolved in 1 mL of DMSO to 20 mL of the nanoparticle concentrations of MTX were obtained by increasing the initial MTX concentration.

Higher concentrations of MTX were obtained by increasing the initial MTX concentration.

Covalent binding of MTX to the HSA-coated and PEG-coated nanoparticles (γ-Fe₂O₃−HSA-MTX, γ-Fe₂O₃−PEG-MTX)

MTX was covalently conjugated to the HSA-coated nanoparticles, γ-Fe₂O₃−HSA. In a typical experiment, 5 mg of MTX dissolved in 2.5 mL of DMSO was added to 2.5 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 5 mg sulfo-NHS dissolved in 2.5 mL of water. The mixture was then shaken at room temperature for 15 minutes. Twenty milliliters of the HSA-coated nanoparticles (γ-Fe₂O₃−HSA, 1 mg/mL) were then added and the mixture was shaken at room temperature for 1 hour, after which the nanoparticles were washed from excess reagents by magnetic columns. In a similar way MTX was conjugated to the terminal NH₂ groups of the γ-Fe₂O₃−PEG-NH₂ nanoparticles. Higher concentrations of MTX were obtained by increasing the initial MTX concentration.

Determination of the bound HSA concentration

The concentration of HSA bound to the γ-Fe₂O₃ nanoparticles was determined by measuring the unbound proteins using the Bradford assay and subtracting it from the initial concentration. The reported values are an average of at least three measurements of each sample. The binding yield was calculated by multiplying the ratio of the concentration of the bound MTX to the initial concentration by 100.

Determination of the bound MTX concentration

The concentration of MTX bound to the γ-Fe₂O₃ nanoparticles was indirectly determined by measuring the absorbance of the unbound drug at 303 nm. The binding yield was calculated by multiplying the ratio of the concentration of the bound MTX to the initial concentration by 100.

Cell culture procedures

9L gliosarcoma cells, which overexpress the folate receptor, were maintained at 37°C and 5% CO₂ in Dulbecco’s Modified Eagle’s Medium (DMEM) (Biological Industries, Kibbutz Beit Haemek, Israel) enriched with 10% FCS and 1% penicillin/streptomycin and subcultured twice a week. The cells were plated at a density of 6 × 10⁶ per well in 24 well plates for the cell-kill experiments and at 1 × 10⁶ per 10 cm plates for the in vitro MRI experiments. The cells were incubated for 24 hours and then treated with the indicated concentration of the therapeutic agents or with the vehicles. Treatment duration was 24 hours for the in vitro MRI experiments and 48 hours for the cell-kill experiments.

In vitro cell-kill experiments

9L cells were treated with the therapeutic agent or with the vehicle for 48 hours. The concentration of the particles was 0.2 mg/mL and the concentration of the bound MTX was 1 µg/mL. The effect of the treatment on cell growth was determined by direct counting of the cells collected from each well using a trypan blue assay. To calculate the average percentage of viable cells, the number of cells counted for each treatment was divided by the number of cells in the control group. The experiment was performed in quadruplicate.

In vitro MRI experiments

In order to determine whether the nanoparticles penetrated the 9L cells efficiently, 9L cells were incubated with γ-Fe₂O₃ nanoparticles and γ-Fe₂O₃−HSA nanoparticles (0.2 mg/mL) for 24 hours. A pellet was prepared from each of the two particle types. The pellet was rinsed twice with PBS and placed in 1.5 mL vials. Calibration vials were prepared with free γ-Fe₂O₃ nanoparticles at concentrations ranging between 0.06–6.0 mg/mL. The two-pellet vials were placed in the MRI coil together with the calibration vials to assess the γ-Fe₂O₃ concentration in the pellets.

In vivo CED experiments

The study was performed in accordance with the guidelines of The Animal Care and Use Committee of Sheba Medical Center, which is recognized by the Israeli authorities for animal experimentation. The CED of nanoparticles was performed into the striatum of normal Sprague-Dawley male rats (280–320 g) under full anesthesia at a rate of 4 µL/min over 15 minutes. Immediately after the infusion the rats
were scanned by gradient-echo MRI for assessment of the nanoparticle distribution, and by T2-weighted MRI for the depiction of procedure-related toxicity. The rats were scanned and weighed once a week for an additional period of 3 weeks for assessment of the toxicity and clearance time of the nanoparticles.

Thirteen rats were treated with CED of γ-Fe$_{2}$O$_{3}$–PEG, 11 rats with γ-Fe$_{2}$O$_{3}$–HSA, 14 rats with γ-Fe$_{2}$O$_{3}$–HSA-MTX, and 11 rats with γ-Fe$_{2}$O$_{3}$.

**CED procedure**

Under full anesthesia, a midline scalp incision was made to identify the bregma. A 1-mm burr hole was made in the right region of the skull, 2 mm lateral and 3 mm posterior to the bregma. A 30-gauge needle attached to a 1000 μL syringe (Gastight; Hamilton Company, Reno, NV) was placed stereotactically 5.5 mm deep in the rat striatum. The infusion was performed using a BASi syringe pump (Bioanalytical Systems Inc, West Lafayette, IN) at a rate of 4 μL/min for 15 minutes.

**Imaging protocol**

Gradient-echo and T2-weighted MR images were acquired using a 1.5T GE MRI system and the standard phased-array GE head-coil. Gradient-echo MRI were acquired with a 512 × 512 matrix, 16 × 12 cm$^2$ field of view, repetition time of 425 ms, echo time of 15 ms, a flip angle of 15° and 2 mm slices with no gap. T2-weighted fast spin echo MRI were acquired with a 512 × 512 matrix, 16 × 12 cm$^2$ field of view, repetition time of 5,500 ms, echo time of 80.2 ms, and 2 mm slices with no gap.

**Calculation of maghemite nanoparticle distribution area**

The area (in mm$^2$) of the infusate distribution was calculated from the gradient-echo MR images. Regions of interest (ROIs) were defined over the entire signal void region in each slice (excluding the ventricles). The number of pixels in the ROIs were counted and multiplied by the volume of a single pixel. Data are presented as mean ± standard deviation (SD).

**Results**

MRI for assessment of γ-Fe$_{2}$O$_{3}$ and γ-Fe$_{2}$O$_{3}$–HSA penetration into the cells: Pellets prepared from 9L cells incubated with γ-Fe$_{2}$O$_{3}$ and γ-Fe$_{2}$O$_{3}$–HSA nanoparticles were placed in the MRI together with calibration vials containing free nanoparticles at concentrations ranging between 0.06–6.0 mg/mL. The MR images (Figure 1) showed that both pellets consisted of 0.2 ± 0.075 mg/mL γ-Fe$_{2}$O$_{3}$.

**In vitro 9L cell-kill experiments**

9L cells were treated with γ-Fe$_{2}$O$_{3}$–PEG, γ-Fe$_{2}$O$_{3}$–PEG-MTX, γ-Fe$_{2}$O$_{3}$–HSA and γ-Fe$_{2}$O$_{3}$–HSA-MTX for 48 hours. The γ-Fe$_{2}$O$_{3}$–HSA particles showed no toxicity: 2% ± 2% cell kill. The γ-Fe$_{2}$O$_{3}$–HSA-MTX showed a similar efficacy to that of free MTX: 63% ± 6% and 77% ± 4% respectively. The

![Figure 1](https://www.dovepress.com/)

**Figure 1** Gradient-echo magnetic resonance images of pellets prepared from 9L cells incubated with 0.2 mg/mL γ-Fe$_{2}$O$_{3}$ and γ-Fe$_{2}$O$_{3}$–HSA and calibration vials containing free maghemite nanoparticles at concentrations ranging from 0.06 mg/mL to 6.0 mg/mL. The magnetic resonance imaging shows that both pellets consisted of 0.2 ± 0.075 mg/mL γ-Fe$_{2}$O$_{3}$. 
γ-Fe$_2$O$_3$–PEG were marginal in means of toxicity: 6% ± 4%, but the efficacy of the γ-Fe$_2$O$_3$–PEG–MTX was relatively low with a wide range of variability: 40% ± 19%.

**In vivo experiments**

The highest average distribution volume, as calculated from the MR images acquired immediately post treatment, was obtained by the CED of γ-Fe$_2$O$_3$–PEG: 118.1 ± 11.3 mm$^3$ (Figure 2). However, this volume was not significantly higher than the volume of distribution of the γ-Fe$_2$O$_3$–HSA: 103.6 ± 13.1 mm$^3$. The distribution of the γ-Fe$_2$O$_3$–HSA–MTX nanoparticles was lower than that of the particles without the drug: 80.2 ± 6.9 mm$^3$. This difference was not significant statistically, although the difference between the γ-Fe$_2$O$_3$–PEG and the γ-Fe$_2$O$_3$–HSA–MTX nanoparticles was significant ($P < 0.0007$, unpaired t test), suggesting that the drug may somewhat impair the efficacy of convection. The naked particles, γ-Fe$_2$O$_3$, showed the lowest volumes of distributions: 36.1 ± 4.4 mm$^3$. These volumes were significantly lower than all the coated particles ($P < 0.0002$ versus γ-Fe$_2$O$_3$–PEG, $P < 0.0008$ versus γ-Fe$_2$O$_3$–HSA and $P < 0.0003$ versus γ-Fe$_2$O$_3$–HSA–MTX, Mann–Whitney test). Examples of the MRI-depicted distributions as a function of time are shown in Figure 3.

The rats were weighed once a week for the duration of the study and the average weight gain was calculated for each group at each time point (Figure 4). All rats gained 16%–17% of their body weight by the end of the 3-week follow-up period: the γ-Fe$_2$O$_3$–PEG group gained 16% ± 2%, the γ-Fe$_2$O$_3$–HSA group 18% ± 1%, the γ-Fe$_2$O$_3$–HSA–MTX group 17% ± 1%, and the γ-Fe$_2$O$_3$ group 18% ± 1%. There were no significant differences among any of the groups, suggesting no apparent toxicity.

Twelve rats died of the anesthesia administered for the MRI follow-ups. This high rate of mortality is attributed to the repeated anesthesia and not to treatment-related toxicity, since all deaths occurred within a few hours of anesthesia administration (the rats never woke up afterwards). In the γ-Fe$_2$O$_3$–PEG group, one rat died following the 2-week follow-up MRI and two rats died following the 3-week MRI. In the γ-Fe$_2$O$_3$–HSA group, one rat died following the 1-week follow-up MRI, one rat died following the 2-week follow-up and one rat died following the 3-week follow-up. In the γ-Fe$_2$O$_3$–HSA–MTX group, one rat died following the 2-week follow-up MRI and two rats died following the 3-week MRI follow-up. In the γ-Fe$_2$O$_3$ group, 1 rat died after the 1-week MRI follow-up and two rats died following the 3-week MRI follow-up. Since there was no difference in mortality among the three groups, and all deaths occurred soon after administration of the anesthesia, it was concluded that mortality was not treatment related.

**Figure 2** Nanoparticle distribution volumes in rat brain as a function of time post-CED treatment for the 4 treatment groups. The distribution volumes were calculated from gradient-echo magnetic resonance images acquired immediately post treatment and 5, 12, and 19 days thereafter.

**Figure 3** Gradient-echo magnetic resonance images of nanoparticle distributions as a function of time for a rat treated with γ-Fe$_2$O$_3$–HSA–MTX (A) and a rat treated with γ-Fe$_2$O$_3$ (B).

**Figure 4** Average relative rat weight gain for each treatment group as a function of time post-CED treatment for the 4 treatment groups.

**Abbreviation:** CED, convection-enhanced delivery; PEG, polyethylene glycol; HSA, human serum albumin; MTX, methotrexate.
Discussion
CED is a novel approach to directly deliver drugs into brain tumors, producing a high concentration of the drug over large volumes within the tumor, while avoiding systemic toxicity. However, initial clinical experience indicates that the main pitfalls of this methodology are the difficulties in forming efficient convection, limited monitoring, and nonspecific toxicity. Efficient CED is currently limited to small molecules. The present study was aimed at applying our increased efficacy and imaging methodologies to enable the efficient CED of drug-loaded nanoparticles, leading the way for therapeutic agents and/or drug carriers that until now were considered inappropriate for convection treatment. Nanoparticles as carriers may enable real-time depiction of the drug distribution, slow drug release, delivery of larger therapeutic agents, and allow targeted drug delivery.

The superparamagnetic maghemite nanoparticles we used are optimal for clinical application due to the uniform nanoparticle population of very narrow size distribution. In order to optimize for the increased efficacy of the nanoparticle distribution in the brain, and in order to obtain efficient binding of the MTX without compromising the efficacy of the drug, coating with both PEG and HSA was studied.

The particles not containing drug – γ-Fe$_2$O$_3$–PEG, γ-Fe$_2$O$_3$–HSA and the naked γ-Fe$_2$O$_3$ particles showed no significant toxicity in vitro, implying that these particles may be used as drug carriers. The particles in which MTX was bound via PEG, γ-Fe$_2$O$_3$–PEG-MTX, showed a low cell-kill efficiency with a wide range of variability, suggesting poor binding of the drug. The nanoparticles in which MTX was bound via a covalent bond to HSA, γ-Fe$_2$O$_3$–HSA-MTX, showed a slightly lower cell-kill efficacy relative to that of the free MTX, likely caused by the uptake difference as the bulkier γ-Fe$_2$O$_3$–HSA-MTX nanoparticles may not be taken up as easily as the free MTX at the same concentration, or by the fact that the MTX may need to be cleaved from the nanoparticles before it shows the toxicity. This is in agreement with the literature,$^{12,14}$ suggesting it may be a good candidate for the delivery of MTX by CED. In one of these studies,$^{14}$ MTX-conjugated nanoparticles were also shown to have targeting specificity for the same tumor cell line (9L rat glioma) used in our study, over a healthy cell line (Cultured Pulmonary Artery Endothelial).

The goal of the in vivo study was to assess the distribution efficacy of the different nanoparticles, to test for toxicity, and to evaluate the clearance time from the tissue. The distribution efficacy of all the coated particles was found to be efficient and significantly higher than that of the naked particles. The PEG coating seemed to provide a similar distribution efficacy to that of the HSA coating since there was no significant difference between the distribution volumes of the γ-Fe$_2$O$_3$–PEG and the γ-Fe$_2$O$_3$–HSA nanoparticles. On the other hand, the γ-Fe$_2$O$_3$–HSA-MTX had slightly lower distribution volumes. There was no significant difference between those and the distribution volumes of the HSA particles without the MTX, but there was a significant difference when comparing the γ-Fe$_2$O$_3$–PEG with the γ-Fe$_2$O$_3$–HSA-MTX, suggesting that the MTX binding may somewhat decrease the distribution efficacy of the particles. However, the distribution volume of the γ-Fe$_2$O$_3$–HSA-MTX particles was more than twice that of the naked particles, implying that these are good candidates for CED treatment. The clearance time of the latter seems to be somewhat slower than that of the other coated particles, resulting in very similar distributions 19 days post treatment.

In this study, we have demonstrated the feasibility of binding an anti-cancer agent, MTX, to biodegradable maghemite nanoparticles, while preserving the penetration of the particles into the cells, and the efficacy of the drug against cancer cells. In addition, we have shown that the chosen formulation provides efficient distributions of the particles in rat brains, depicted by MRI in real time, with no apparent toxicity, and that the clearance time of the particles is long, enabling slow drug release.

Acknowledgments
This research was funded by The Goldhirsh Foundation Brain Tumor Research Awards Program. The authors thank Louise Braverman for her help in editing the final manuscript.

Disclosure
Some of the authors are inventors of relevant patents. The authors have no other conflicts of interest to declare in relation to this work.

References


